Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR3A | P46098 | 3/20 | 0.59 |
| ▸ | MEN1 | O00255 | 2/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.58 |
| ▸ | POLB | P06746 | 1/20 | 0.58 |
| ▸ | EPHX2 | P34913 | 5/20 | 0.53 |
| ▸ | CNR1 | P21554 | 1/20 | 0.51 |
| ▸ | MCHR1 | Q99705 | 2/20 | 0.49 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.48 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | TP53 | P04637 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5409909 | 0.89 | MCHR1 (0.56) | MEN1KMT2APOLBEPHX2CNR1 | |
| SCHEMBL8296783 | 0.82 | POLB (0.58) | HTR3AMEN1KMT2APOLBEPHX2 | |
| SCHEMBL10923255 | 0.76 | KMT2A (0.97) | HTR3AMEN1KMT2APOLBCNR1 | |
| SCHEMBL5406900 | 0.76 | DRD2 (0.53) | MEN1KMT2APOLBRAB9A | |
| SCHEMBL13527422 | 0.75 | HTR3A (1.00) | HTR3AMEN1KMT2APOLBCHRNA7 | |
| SCHEMBL7238389 | 0.75 | HPGD (0.67) | HTR3AMEN1KMT2APOLBEPHX2 | |
| SCHEMBL10553825 | 0.74 | KMT2A (1.00) | HTR3AMEN1KMT2APOLBCNR1 | |
| SCHEMBL10921358 | 0.74 | KMT2A (1.00) | HTR3AMEN1KMT2APOLBCNR1 | |
| Bromide SCHEMBL10555741 | 0.74 | KMT2A (0.94) | HTR3AMEN1KMT2APOLBCNR1 | |
| SCHEMBL8296733 | 0.74 | HTR3A (0.59) | HTR3AMEN1KMT2APOLBCNR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7202269-B2 | GlyT2 modulators | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-04-10 | — | — | US | claimed |
| US-20050119245-A1 | GlyT2 modulators | JANSSEN PHARMACEUTICA, N.V. (BE) | 2005-06-02 | — | — | US | claimed |
| US-7202269-B2 | GlyT2 modulators | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-04-10 | — | — | US | disclosed |
| US-7202269-B2 | GlyT2 modulators | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-04-10 | — | — | US | disclosed |
| US-7202269-B2 | GlyT2 modulators | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-04-10 | — | — | US | disclosed |
| US-20050119245-A1 | GlyT2 modulators | JANSSEN PHARMACEUTICA, N.V. (BE) | 2005-06-02 | — | — | US | disclosed |
| WO-2005044810-A1 | GLYT2 MODULATORS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2005-05-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050119245-A1 | GlyT2 modulators | GLRB, GLRA1, GLRA2 | HTR3A 702/4885MEN1 1713/4885KMT2A 650/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.